AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline

Bernstein Liebhard LLP reminded Aardvark Therapeutics investors of an October 13, 2026 deadline related to a securities-fraud class action against the company. The notice creates legal and reputational risk for NASDAQ-listed Aardvark (AARD), though the article provides no details on alleged damages, claims, or expected financial exposure.

Analysis

This is a low-information legal-advertisement signal rather than a fundamental catalyst. The filing deadline itself does not establish liability, damages, or a change in AARD's operating outlook; absent a newly disclosed adverse clinical, regulatory, or commercial fact, the expected incremental valuation impact is limited. Near-term pressure can still arise from retail-holder uncertainty and reduced willingness of marginal buyers to provide liquidity, particularly if AARD has a small float and elevated borrow cost.

The investable question is whether the underlying alleged disclosure event creates a durable revision to probability-adjusted pipeline value. For a clinical-stage biotech, even a modest decline in perceived approval probability or addressable-market assumptions can materially compress equity value, while legal expense is generally immaterial relative to trial, FDA, and financing risks. Over the next 1-3 months, monitor any amended complaint, company insurance disclosure, insider transactions, cash-runway update, and trial/regulatory milestones; those items—not the October deadline—would determine whether the litigation becomes a tradable fundamental impairment.

Contrarianly, a headline-driven selloff could create a tactical long only if the alleged facts are already fully disclosed, no regulator opens a parallel investigation, and cash runway remains sufficient through the next value-inflecting data event. Conversely, a short is unattractive solely on this notice: biotech downside is often already reflected after the initial disclosure, while squeeze risk is high if clinical data, partnership news, or financing arrives. The thesis is falsified by an SEC/FDA inquiry, a material guidance or trial-timeline delay, or evidence that the disputed statements affected a financing or key development program.

Key Decisions for Investors

• No standalone position from this notice. Place AARD on an event watchlist through the October 13 deadline; act only on primary-source complaint allegations and the company’s underlying corrective disclosure.
• For existing AARD longs, reduce gross exposure or hedge into the next clinical/regulatory catalyst if borrow/liquidity permits; use a break below the post-corrective-disclosure low as a risk trigger rather than the lawsuit deadline.
• Consider a tactical long only after verifying three conditions: no parallel SEC/FDA action, cash runway extends beyond the next major readout, and shares stabilize above the corrective-disclosure low for 5-10 trading sessions. Size modestly given binary biotech risk.
• If a parallel regulatory inquiry or a trial delay emerges, favor a 1-3 month short/put structure in AARD rather than waiting for civil-litigation milestones; reassess immediately if the company announces positive data or non-dilutive funding.